NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with advanced NSCLC who have progressed after at least previous anti-PD-(L)1 treatment and are ECOG 0-1 are allowed to participate irrespective of the level of tumor PD-L1 expression. Patients with advanced NSCLC with a targetable driver mutation may be found eligible, but only when all options for targeted therapy have been exhausted and when progression on previous PD-(L)1 blockade has occurred.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.